Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04586075
Other study ID # 2020-0700
Secondary ID SMPHProtocol Ver
Status Recruiting
Phase
First received
Last updated
Start date July 16, 2021
Est. completion date October 2025

Study information

Verified date October 2023
Source University of Wisconsin, Madison
Contact Jadin Heilmann
Phone (608) 263-5877
Email research@CHGPM.wisc.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary purpose of this study is to discover new disease genes for rare Mendelian disorders and its secondary purpose include diagnosing people with rare genetic disorders that have not been previously diagnosed through conventional clinical means, learning more about the pathobiology of genetic disorders, and developing novel diagnostic technologies and analytics. 500 participants with undiagnosed and suspected genetic disorders will be recruited over approximately 5 years time.


Description:

An estimated 10,000 rare Mendelian genetic disorders affect, in aggregate, one in twelve individuals. Importantly, just over half of these diseases have a known genetic cause. This leaves thousands of disease genes waiting to be discovered and millions of affected individuals without a diagnosis. The investigators will address these critical issues in genomic medicine by using genome sequencing and other 'omics technologies to assess patients whose comprehensive clinical workups have failed to yield a diagnosis. The hypothesis is that, when carefully selected, these undiagnosed disease patients will be a rich resource for new disease gene discovery. This study is the research arm of the UW Undiagnosed Disease program (UW-UDP). The primary objective of this study is to discover new disease genes and expand the known phenotypes of rare Mendelian disorders. The secondary objectives are: a) Diagnose individuals with genetic disorders who have not been diagnosed using conventional clinical means and provide them with actionable knowledge to manage their disorders; b) Improve our understanding of the pathobiology of genetic disorders and the relationships between genomic variation and disease; and c) Develop and trial novel diagnostic technologies and analytics. These objectives will be achieved through three aims: Aim 1: Identify candidate disease variants in individuals suspected of an undiagnosed genetic disorder through the use of trio short read genome sequencing and data sharing with the rare disease databases GeneMatcher and MatchMaker Exchange. Aim2: Further evaluate those individuals not diagnosed in Aim 1 by using novel 'omics technologies and bioinformatics algorithms. These approaches include a) ultra-long read de novo assembly-based genomic sequencing; b) RNA-Seq; c) epigenomics profiling, and d) conformational analysis of chromatin organization. Aim 3: Provide functional assessments of selected candidate disease genes and genomic variants discovered in Aims 1 and 2 through collaborations with UW and external model organism researchers. These efforts will be facilitated through the use of a UW model organism researcher database that is linked to the Canadian Rare Diseases Models and Mechanisms Network database and an emerging global network of model organism researcher databases. This research project is closely integrated with the UW-UDP's comprehensive clinical evaluations of undiagnosed patients. The standard clinical care component entails patient referral, collection and pre-visit assessment of medical records, and clinic visits for extensive phenotyping at the beginning of the study and for the return of results at the end of the study. The research workflow includes genome sequencing, data sharing with global disease gene discovery networks, and follow-up studies to determine causality of variants identified by genetic testing. This study will advance understanding of the pathobiology of genetic disease, improve clinical diagnostics, and aid in the diagnosis and management of individuals with previously undiagnosed rare disorders both within Wisconsin and beyond its borders.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date October 2025
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 100 Years
Eligibility Inclusion Criteria: - The applicant has a condition that remains undiagnosed despite thorough evaluation by healthcare providers (including clinical genetic testing). - The applicant has at least one objective finding that is likely to have an identifiable genetic etiology. - The applicant likely has a currently undescribed/new genetic condition or a known genetic condition associated with a novel gene. - The applicant/legal guardian agrees to the collection, storage and recurrent sharing of coded information and biomaterials for research and diagnostic purposes both within and outside of the University of Wisconsin-Undiagnosed Diseases Program (UW-UDP) - The applicant/legal guardian agrees to receive secondary findings from genetic testing. - The applicant/legal guardian has sufficient proficiency in English to understand the consent. Exclusion Criteria: - The applicant already has a diagnosis that explains the objective findings. - A specific diagnosis is suspected and a standard clinical workup performed by the referring/primary care provider would be appropriate. - The UW-UDP is unlikely to improve on the comprehensive workup the applicant has already received. - The applicant's symptoms are likely multifactorial or due to a non-genetic cause.

Study Design


Intervention

Diagnostic Test:
Trio Whole Genome Sequencing and Participant-Specific Research
The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents). Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses

Locations

Country Name City State
United States University of Wisconsin School of Medicine and Public Health Madison Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison University of Wisconsin Center for Human Genomics and Precision Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of New Disease Genes Discovered up to 5 years
Primary Number of Expanded Disease Gene Phenotypes up to 5 years
Secondary Number of Participants who are Diagnosed in 5 years A secondary objective of this study is to diagnose individuals with genetic disorders who have not been diagnosed using conventional clinical means and provide them with actionable knowledge to manage their disorders. This will be measured as the rate of diagnosis over the entire study. up to 5 years
Secondary Number of Participants Diagnosed per Analytical Technique A secondary aim of this study is to develop and trial novel diagnostic technologies and analytics. The diagnosis rate per novel analytic technique will be assessed. up to 5 years
Secondary Diagnostic Rate by Disease Presentation To improve understanding of the pathobiology of genetic disorders and the relationships between genomic variation and disease, number of participants diagnosed by disease presentation will be reported. up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03292302 - Phase 1 Study of ELX-02 in Healthy Adults Phase 1
Withdrawn NCT03658382 - Virtual Visits for Results Disclosure N/A
Recruiting NCT02266615 - Biobank Clinical Genetics Maastricht (KG01)
Recruiting NCT02450851 - Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Recruiting NCT05472714 - Educational Video for Genetic Testing N/A
Recruiting NCT04285814 - Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
Completed NCT05443113 - Young Pectus Excavatum Patients and Genetic Defects
Completed NCT05655741 - Modified Delphi for Genomic Bereavement Care
Completed NCT03847909 - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02225522 - Genomic Sequencing in Acutely Ill Neonates N/A
Enrolling by invitation NCT06089954 - Penn Medicine Biobank Return of Results Program N/A
Completed NCT03713333 - Implementing Digital Health in a Learning Health System N/A
Completed NCT03309605 - Phase 1 Study of ELX-02 in Healthy Adult Subjects Phase 1
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT04556500 - Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
Completed NCT04556487 - Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Recruiting NCT02551081 - Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units